Cantor Fitzgerald Estimates PLRX FY2025 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Pliant Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings per share of ($4.46) for the year. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.65) per share.

Separately, HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pliant Therapeutics in a research note on Friday, November 8th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Pliant Therapeutics has a consensus rating of “Buy” and an average target price of $40.50.

Pliant Therapeutics Trading Down 1.2 %

Shares of PLRX opened at $11.07 on Wednesday. The business has a 50-day simple moving average of $13.29 and a two-hundred day simple moving average of $13.07. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26. Pliant Therapeutics has a 52 week low of $10.22 and a 52 week high of $18.92.

Pliant Therapeutics (NASDAQ:PLRX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.04.

Institutional Trading of Pliant Therapeutics

Several institutional investors have recently made changes to their positions in the business. Great Point Partners LLC grew its stake in Pliant Therapeutics by 42.4% during the second quarter. Great Point Partners LLC now owns 2,636,864 shares of the company’s stock valued at $28,346,000 after acquiring an additional 785,000 shares in the last quarter. State Street Corp boosted its stake in Pliant Therapeutics by 1.9% during the third quarter. State Street Corp now owns 1,402,730 shares of the company’s stock valued at $15,725,000 after buying an additional 26,610 shares during the last quarter. Geode Capital Management LLC grew its holdings in Pliant Therapeutics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,318,308 shares of the company’s stock valued at $14,781,000 after buying an additional 31,221 shares in the last quarter. Franklin Resources Inc. increased its stake in Pliant Therapeutics by 1.5% in the 3rd quarter. Franklin Resources Inc. now owns 1,039,904 shares of the company’s stock worth $11,657,000 after acquiring an additional 14,913 shares during the last quarter. Finally, Fernwood Investment Management LLC raised its holdings in shares of Pliant Therapeutics by 3.4% during the 3rd quarter. Fernwood Investment Management LLC now owns 513,136 shares of the company’s stock worth $5,752,000 after acquiring an additional 16,850 shares in the last quarter. Hedge funds and other institutional investors own 97.30% of the company’s stock.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.